文献速递甲状腺疾病

免疫检查点抑制剂联合酪氨酸激酶抑制剂对甲状腺功能的共同影响

The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
PubMed 文献 · Thyroid · 2024-01-08

一项回顾性队列研究纳入2017至2023年在City of Hope综合癌症中心接受ICI+TKI联合治疗且治疗前TSH正常的106例患者,中位年龄63.5岁,中位随访12.8个月。63.2%(67/106)出现甲状腺功能异常,包括甲状腺功能亢进11例(10.4%)、亚临床甲状腺功能减退42例(39.6%)、明显甲状腺功能减退14例(13.2%)。作者认为甲状腺功能障碍是联合治疗的常见不良事件,起病快、发生率高于单用ICI或TKI,推荐治疗初期密切监测甲状腺功能并联合内分泌科多学科管理。

要点

  • ICI+TKI联合治疗患者中63.2%(67/106)出现甲状腺功能异常。
  • 甲状腺功能亢进11例(10.4%)、亚临床甲状腺功能减退42例(39.6%)、明显甲状腺功能减退14例(13.2%)。
  • 甲状腺功能异常起病中位时间分别为甲状腺功能亢进7周、亚临床甲状腺功能减退8.0周、明显或加重甲状腺功能减退8.1周。

核心结论

  • 甲状腺功能障碍是ICI+TKI联合治疗中常见的不良事件,数据提示起病快、发生率高于既往单用ICI或TKI治疗。

研究设计与样本

  • 回顾性队列研究,纳入2017至2023年在City of Hope综合癌症中心接受ICI+TKI联合抗癌治疗且治疗前促甲状腺激素(TSH)正常的患者106例,中位年龄63.5岁,中位随访12.8个月(四分位距[IQR] 5.9-20.9)。

主要发现

  • 63.2%(67/106)在ICI+TKI治疗期间出现甲状腺功能异常,其中甲状腺功能亢进11例(10.4%)、亚临床甲状腺功能减退42例(39.6%)、明显甲状腺功能减退14例(13.2%)。
  • 甲状腺功能异常起病中位时间:甲状腺功能亢进为ICI+TKI治疗开始后7周(IQR 3.1-9.0),亚临床甲状腺功能减退为8.0周(IQR 3.0-19.0),明显或加重甲状腺功能减退为8.1周(IQR 5.9-9.1)。
  • 所有甲状腺功能亢进受试者未经干预即转为甲状腺功能减退或TSH正常,提示甲状腺炎;甲状腺功能减退经甲状腺激素替代治疗即可控制。

临床怎么用

  • 作者推荐在初始治疗期间密切监测甲状腺功能,并与内分泌科多学科协作,以便早期发现并及时启动甲状腺激素替代治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Recent successes with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) for the treatment of solid malignancies have paved the way for a new era of combined therapy. A common side effect seen with each of these classes of treatment is thyroid dysfunction, with rates estimated at 30-40% for TKI and 10-20% for ICI. However, little is known about the effect of combined ICI+TKI therapy on thyroid function. Therefore, this study evaluated the incidence, clinical features, and risk factors for developing thyroid abnormalities during ICI+TKI therapy and the relationship to cancer outcomes. Methods: We conducted a retrospective cohort study of patients treated with combination ICI+TKI cancer therapy at City of Hope Comprehensive Cancer Center from 2017 to 2023 who had pretreatment normal thyrotropin (TSH) levels. Primary analyses assessed the frequency, timing, and severity of thyroid function test abnormalities during ICI+TKI cancer therapy, and the requirement for thyroid hormone replacement. Secondary analyses evaluated risk factors for the development of thyroid dysfunction, including sex and drug regimen, and the association with cancer progression-free survival or overall survival. Univariable and multivariable models were used. Results: There were 106 patients who received ICI+TKI therapy with a median age of 63.5 years and a median follow-up of 12.8 months (interquartile range [IQR] 5.9-20.9). Notably, 63.2% (67/106) developed thyroid function abnormalities during ICI+TKI therapy, including 11 (10.4%) with hyperthyroidism, 42 (39.6%) with subclinical hypothyroidism (SCHypo), and 14 (13.2%) with overt hypothyroidism. The onset of thyroid dysfunction occurred at a median of 7 weeks (IQR 3.1-9.0) after start of ICI+TKI treatment for hyperthyroidism, 8.0 weeks (IQR 3.0-19.0) for SCHypo, and 8.1 weeks (IQR 5.9-9.1) for overt or worsening hypothyroidism. Hyperthyroidism resolved to hypothyroidism or normal TSH without intervention in all subjects, suggesting thyroiditis, and hypothyroidism was readily treated with thyroid hormone replacement. Conclusions: Thyroid dysfunction is a frequent adverse event in individuals treated with combination ICI+TKI therapy, with our data suggesting a rapid onset and higher incidence than previously seen with ICI or TKI therapy alone. Therefore, close monitoring of thyroid function during initial therapy and multidisciplinary care with endocrinology are recommended to facilitate early detection and initiation of thyroid hormone replacement in these patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Tsai K, Ma H, Liang TZ, et al. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function. Thyroid. 2024. PMID: 38069567. doi:10.1089/thy.2023.0542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。